Delivery Order SPE2DR25D7005-SPE2DR26F3FCS
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order valued at $1,562.33 to AmerisourceBergen Drug Corp for Coartem Tablets 24S, a pharmaceutical product used in malaria treatment. The contract is non-competitive and employs firm fixed-price pricing, with a completion date of January 9, 2026. AmerisourceBergen Drug Corp, headquartered in Conshohocken, Pennsylvania, is a major pharmaceutical distributor serving federal medical procurement needs, particularly for military and veteran...
- The Defense Logistics Agency's Medical Supply Chain awarded a $1,238.07 delivery order to AmerisourceBergen Drug Corp on April 23, 2025, for Coartem Tablets 24S, an antimalarial medication commonly used for treatment of malaria in military and defense health applications. This non-competitive, firm fixed-price delivery order, which is due for completion by April 24, 2025, represents a discrete purchase against AmerisourceBergen's larger indefinite delivery contract vehicle with DLA Troop Support...
- The Defense Logistics Agency awarded a $74,899.88 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Artesunate 110 mg vials, with an ultimate completion date of February 18, 2026. This non-set-aside contract was competitively awarded and represents a task order executed under AmerisourceBergen's parent company Cencora, Inc.'s larger Indefinite Delivery Contract with DLA Troop Support Medical, valued at $999.99 million through December 2031. The delivery will be...
- Amerisourcebergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order valued at $34,045.40 by the Defense Logistics Agency on January 23, 2026, for the supply of Artesunate 110 mg vials. The contract carries a firm fixed price structure with no set-aside designation, indicating it was competitively awarded. The ultimate completion date is February 13, 2026, and the place of performance is located at the awardee's corporate...
- The Defense Logistics Agency (DLA) awarded a $20,786.31 delivery order to AmerisourceBergen Drug Corp for the supply of Artesunate 110 mg vials, with a completion date of September 22, 2025. This competitively awarded, firm fixed-price contract represents a child order under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical (SPE2DX), valued at $999.999 billion and extending through December 2026. The contract includes no set-aside designation,...
- The Defense Logistics Agency's Medical Supply Chain awarded a $6,928.76 firm fixed-price delivery order to AmerisourceBergen Drug Corp for 110 mg Artesunate vials, with an ultimate completion date of May 23, 2025. This non-set-aside competitive award represents a child delivery order issued under AmerisourceBergen's larger Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, valued at $999,999,999.00 through December 2026. The award was issued to the contractor's Corporate Office...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on December 16, 2025, for the supply of Malarone 250-100 mg tablets (100 count) with a ceiling value of $7,755.83. This firm fixed price delivery order, with an ultimate completion date of December 17, 2025, represents a competitively awarded, non-set-aside contract. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. This delivery order is issued under the company's...
- The Defense Logistics Agency awarded a $9,224.34 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Malarone 250/100 (100 tablets) on January 15, 2026, with an ultimate completion date of January 16, 2026. This non-set-aside award was performed at the contractor's facility in Conshohocken, Pennsylvania. AmerisourceBergen Drug Corp, a subsidiary of parent company Cencora, Inc., is a major pharmaceutical distributor serving as a critical vendor for federal medical...
- The Defense Logistics Agency awarded a delivery order valued at $8,605.46 to AmerisourceBergen Drug Corp on January 29, 2026, for the supply of Malarone 250/100 (100 tablets), an antimalarial medication. This firm fixed-price delivery order, which is not set-aside for any specific business category, is scheduled for completion by February 26, 2026, with performance taking place at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. The award represents a child contract under...
- The U.S. Defense Medical Supply Chain awarded a $5,859 delivery order to AmerisourceBergen Drug Corp for Malarone 250/100 (100 tablets), a pharmaceutical antimalarial medication. This competitively awarded, firm fixed-price contract has an ultimate completion date of September 16, 2025, and represents a child delivery order under AmerisourceBergen's larger Indefinite Delivery Contract with the Defense Logistics Agency. The work will be performed at the contractor's corporate office in...
- SPE2DR25D7005Indefinite Delivery Contract
- SPE2DR25D7005-SPE2DR26F3FCSDelivery Order
The Defense Logistics Agency awarded a $1,740.83 firm fixed-price delivery order to AmerisourceBergen Drug Corp (parent company Cencora, Inc.) on January 29, 2026, for Coartem Tablets 24S, with completion scheduled for January 30, 2026. This delivery order is issued under AmerisourceBergen's substantial Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), valued at up to $999,999,999.00 and extending through December 2026. The contract was awarded on a non-set-aside, fully competitive basis, reflecting the contractor's demonstrated capability to meet federal pharmaceutical procurement requirements. The place of performance is AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. As a leading pharmaceutical distributor for federal healthcare systems, AmerisourceBergen serves critical medical supply needs for military treatment facilities, the Defense Health Agency, U.S. Coast Guard, and other government healthcare programs. Coartem (artemether-lumefantrine) is an antimalarial combination medication, consistent with the company's extensive portfolio of brand-name and generic drugs, specialty medications, and medical supplies spanning multiple therapeutic domains. This delivery order represents a routine pharmaceutical fulfillment under the company's established prime vendor relationship with DLA, which enables flexible and efficient medical supply chain support for Department of Defense healthcare operations worldwide.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.7k | 1/28/26 |